Stock Price
71.47
Daily Change
-1.25 -1.72%
Monthly
-0.32%
Yearly
55.34%
Q2 Forecast
72.16

PTC Therapeutics reported $81.47M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 169.18M 470K Dec/2025
Alnylam Pharmaceuticals USD 133.44M 1.07M Mar/2026
Amgen USD 540M 1000K Mar/2026
BioCryst Pharmaceuticals USD 213.06M 2.54M Dec/2025
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 193.27M 969K Mar/2026
Cytokinetics USD 124.43M 2.17M Mar/2026
Daiichi Sankyo JPY 1.85B 9K Dec/2025
Enanta Pharmaceuticals USD 212K 1000 Dec/2023
Esperion Therapeutics USD 245.22M 39.79M Dec/2025
Gilead Sciences USD 1.24B 1000K Mar/2026
Incyte USD 199.95M 1.49M Mar/2026
Ionis Pharmaceuticals USD 165.9M 3.93M Mar/2026
Ironwood Pharmaceuticals USD 160K 0 Dec/2024
Karyopharm Therapeutics USD 18.31M 18.3M Dec/2025
Novartis USD 1.91B 60K Mar/2026
Pfizer USD 5.7B 13M Mar/2026
PTC Therapeutics USD 81.47M 1.54M Dec/2025
Puma Biotechnology USD 5K 0 Jun/2024
Roche Holding CHF 795.62M 699.54K Dec/2025
Sarepta Therapeutics USD 105.57M 607K Mar/2026
TG Therapeutics USD 155.31M 95K Dec/2025
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
Vertex Pharmaceuticals USD 254.2M 200K Mar/2026
Xencor USD 74.06M 2.19M Mar/2026